Preclinical

A Powerful Form of
Immunotherapy

Emerging as one of the most innovative and promising cancer treatments today, CAR T-cell therapy has proved to provide clinicial benefit in multiple types of cancer. However, it doesn't come without risks and there are challenges to be considered when it comes to understanding the power of this therapeutic advancement and how to leverage it.

Guidelines for Organizations Looking to Explore CAR T-Cell Therapy

Before embarking on the develppment of a new CAR T-cell therapy, keep in mind that although this treatment could provide significant benefit to patients, it is a complex and expensive therapy. Consider the following when planning your preclinical development path:

• Identify the type of cancer model you plan to treat and ensure growth in an in vivo setting
• Prepare your CAR T-cell therapy for administration
• Understand study duration and treatment persistence

Contact Us

Ready to get started?

If you're seeking a partner who can help set your oncology drug program up for success from the onset, we can help.

"TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR T-cell mouse studies across multiple antigen targets in a number of oncology indications," says Dr. Jon Terrett, Head of Immuno-Oncology Research and Translation at CRISPR Therapeutics.

We specialize in oncology-it's all we do-and our expert team aims to save you time, money and resources.

Contact us to get started today.

Unmatched Scientific Expertise | Accelerated Development | Committed to Your Goals | Patient-Centered

THE PRECISION ONCOLOGY CRO™

Connect with us on LinkedIn

www.td2inc.com